Delcath Systems’ (DCTH) Buy Rating Reaffirmed at HC Wainwright

Delcath Systems (NASDAQ:DCTH)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $22.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 126.80% from the stock’s current price.

A number of other brokerages also recently issued reports on DCTH. Stephens reissued a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. Canaccord Genuity Group reiterated a “buy” rating and set a $21.00 target price on shares of Delcath Systems in a research report on Friday, October 18th. Finally, StockNews.com raised Delcath Systems from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $21.50.

Delcath Systems Stock Performance

NASDAQ:DCTH opened at $9.70 on Monday. The firm has a market cap of $269.56 million, a price-to-earnings ratio of -7.38 and a beta of 0.75. Delcath Systems has a 52 week low of $2.25 and a 52 week high of $12.88. The firm’s 50-day simple moving average is $9.76 and its 200 day simple moving average is $8.40.

Hedge Funds Weigh In On Delcath Systems

Several hedge funds and other institutional investors have recently modified their holdings of the business. Rosalind Advisors Inc. boosted its stake in Delcath Systems by 155.1% in the second quarter. Rosalind Advisors Inc. now owns 2,650,389 shares of the company’s stock valued at $22,184,000 after buying an additional 1,611,561 shares in the last quarter. AIGH Capital Management LLC grew its holdings in shares of Delcath Systems by 1.7% during the 2nd quarter. AIGH Capital Management LLC now owns 2,399,792 shares of the company’s stock valued at $20,086,000 after purchasing an additional 40,064 shares during the last quarter. BVF Inc. IL increased its position in Delcath Systems by 23.1% during the 1st quarter. BVF Inc. IL now owns 1,202,067 shares of the company’s stock worth $5,734,000 after purchasing an additional 225,918 shares in the last quarter. Vanguard Group Inc. lifted its stake in Delcath Systems by 31.0% in the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock valued at $3,261,000 after purchasing an additional 161,678 shares during the last quarter. Finally, Shellback Capital LP acquired a new stake in Delcath Systems in the second quarter valued at approximately $1,353,000. Institutional investors own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.